Rakuten Investment Management Inc. Raises Stock Holdings in Gilead Sciences, Inc. $GILD

Rakuten Investment Management Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 252.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 230,184 shares of the biopharmaceutical company’s stock after buying an additional 164,784 shares during the quarter. Rakuten Investment Management Inc.’s holdings in Gilead Sciences were worth $28,752,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of GILD. Quattro Advisors LLC purchased a new position in Gilead Sciences in the 4th quarter worth about $26,000. Ares Financial Consulting LLC purchased a new position in Gilead Sciences in the 4th quarter worth about $28,000. Financial Consulate Inc. raised its position in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares during the last quarter. North Star Investment Management Corp. raised its position in Gilead Sciences by 54.8% in the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 86 shares during the last quarter. Finally, BOCHK Asset Management Ltd purchased a new position in Gilead Sciences in the 4th quarter worth about $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on GILD. Jefferies Financial Group began coverage on Gilead Sciences in a research report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price for the company. Mizuho boosted their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Citigroup boosted their target price on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. The Goldman Sachs Group boosted their price target on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Finally, Argus increased their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $124.30 on Tuesday. The firm has a 50 day moving average of $132.86 and a 200 day moving average of $134.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $154.33 billion, a price-to-earnings ratio of 16.93 and a beta of 0.31. Gilead Sciences, Inc. has a 12-month low of $104.46 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is 44.69%.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 62,000 shares of company stock worth $8,182,190. 0.30% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.